



ISL/LEN Phase 3 Development Program

PWH with Virologic Suppression




How many participants in the study had undetectable HIV levels after 48 weeks?

Weekly ISL/LEN:



0 participants had detectable HIV levels and 20 had no data


Daily B/F/TAF:




1 participant had detectable HIV levels and 22 had no data

How many participants in the study had undetectable HIV levels after 48 weeks?

Weekly ISL/LEN:




Daily SOC:




How many participants were satisfied with ISL/LEN treatment?

Treatment satisfaction:



Most participants were "much more satisfied" or "more satisfied" with ISL/LEN than with standard HIV treatment

Treatment burden:



Most participants felt that standard HIV treatment was harder to manage than ISL/LEN

Glossary

- SOC: Standard of care
- PWH: People with HIV-1
- STR: Single-tablet regimen
- ISL/LEN: islatravir + lenacapavir
- B/F/TAF: bictegravir/emtricitabine/tenofovir alafenamide